These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 18641556

  • 1. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period.
    Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A, Jouault H, Astier A, Tod M, Hulin A.
    Ther Drug Monit; 2008 Aug; 30(4):412-8. PubMed ID: 18641556
    [Abstract] [Full Text] [Related]

  • 2. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
    Blanchet B.
    Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908
    [Abstract] [Full Text] [Related]

  • 3. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR, Vanrenterghem Y.
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients.
    Jain A, Venkataramanan R, Sharma R, Kwong T, Orloff M, Abt P, Kashyap R, Tsoulfas G, Batzold P, Williamson M, Bozorgzadeh A.
    Transplantation; 2008 Feb 27; 85(4):554-60. PubMed ID: 18347534
    [Abstract] [Full Text] [Related]

  • 5. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ.
    Ther Drug Monit; 2009 Apr 27; 31(2):187-97. PubMed ID: 19258929
    [Abstract] [Full Text] [Related]

  • 6. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P, Press RR, den Hartigh J, Cremers SC, Baranski AG, Lamers CB, Hommes DW, van Hoek B.
    Ther Drug Monit; 2008 Aug 27; 30(4):456-61. PubMed ID: 18641539
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
    Fukudo M, Yano I, Masuda S, Fukatsu S, Katsura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K.
    Clin Pharmacol Ther; 2005 Aug 27; 78(2):168-81. PubMed ID: 16084851
    [Abstract] [Full Text] [Related]

  • 8. Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients.
    Dansirikul C, Staatz CE, Duffull SB, Taylor PJ, Lynch SV, Tett SE.
    J Clin Pharm Ther; 2006 Feb 27; 31(1):17-25. PubMed ID: 16476116
    [Abstract] [Full Text] [Related]

  • 9. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation.
    Staatz CE, Taylor PJ, Lynch SV, Tett SE.
    Liver Transpl; 2004 Apr 27; 10(4):506-12. PubMed ID: 15048793
    [Abstract] [Full Text] [Related]

  • 10. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L, Aguilera-García I, Docobo-Pérez F, Alamo-Martínez JM, Pareja-Ciuró F, Nuñez-Roldán A, Gómez-Bravo MA, Bernardos-Rodríguez A.
    Transplant Proc; 2008 Nov 27; 40(9):2949-51. PubMed ID: 19010156
    [Abstract] [Full Text] [Related]

  • 11. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE, Tett SE.
    Eur J Clin Pharmacol; 2002 Dec 27; 58(9):597-605. PubMed ID: 12483452
    [Abstract] [Full Text] [Related]

  • 12. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence.
    Venkat VL, Nick TG, Wang Y, Bucuvalas JC.
    Pediatr Transplant; 2008 Feb 27; 12(1):67-72. PubMed ID: 18186891
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
    Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE.
    Ther Drug Monit; 2011 Dec 27; 33(6):663-72. PubMed ID: 22105583
    [Abstract] [Full Text] [Related]

  • 14. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation.
    Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE.
    Liver Transpl; 2003 Feb 27; 9(2):130-7. PubMed ID: 12548506
    [Abstract] [Full Text] [Related]

  • 15. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
    Ogino S, Hashikura Y, Katsuyama Y, Ikegami T, Nakazawa Y, Urata K, Terada M, Miyagawa S, Kawasaki S.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):299S-301S. PubMed ID: 15041357
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB, Karamperis N, Jørgensen KA.
    Transplant Proc; 2005 May 27; 37(4):1736-8. PubMed ID: 15919449
    [Abstract] [Full Text] [Related]

  • 17. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients.
    Zhang XQ, Wang ZW, Fan JW, Li YP, Jiao Z, Gao JW, Peng ZH, Liu GL.
    Ther Drug Monit; 2012 Apr 27; 34(2):126-33. PubMed ID: 22377746
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
    Bartlomiejczyk I, Zochowska D, Sanko-Resmer J, Matuszewicz D, Paczek L.
    Transplant Proc; 2006 Apr 27; 38(1):94-6. PubMed ID: 16504673
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation.
    Sæves I, Line PD, Bremer S, Vethe NT, Tveit RG, Meltevik TJ, Bergan S.
    Ther Drug Monit; 2014 Feb 27; 36(1):46-53. PubMed ID: 24081206
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.
    Lemaitre F, Blanchet B, Latournerie M, Antignac M, Houssel-Debry P, Verdier MC, Dermu M, Camus C, Le Priol J, Roussel M, Zheng Y, Fillatre P, Curis E, Bellissant E, Boudjema K, Fernandez C.
    Clin Biochem; 2015 Apr 27; 48(6):406-11. PubMed ID: 25562187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.